<![CDATA[Ferrer 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=41343>Sat, 07 Mar 2026 09:33:31 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule]]>https://www.newswire.co.kr/newsRead.php?no=1021145Wed, 22 Oct 2025 15:55:00 +0900<![CDATA[페레, 진행성 핵상 마비에 대한 제2상 임상 시험인 PROSPER 시험 위해 예정보다 2개월 앞당겨 220명의 환자 모집 완료]]>https://www.newswire.co.kr/newsRead.php?no=1021146Wed, 22 Oct 2025 15:55:00 +0900<![CDATA[Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)]]>https://www.newswire.co.kr/newsRead.php?no=1013366Wed, 18 Jun 2025 17:50:00 +0900<![CDATA[페레, 진행성 핵상마비 치료제 FNP-223에 대한 FDA 신속 심사 지정 획득]]>https://www.newswire.co.kr/newsRead.php?no=1013368Wed, 18 Jun 2025 17:50:00 +0900<![CDATA[Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine]]>https://www.newswire.co.kr/newsRead.php?no=1010281Tue, 29 Apr 2025 09:50:00 +0900<![CDATA[페레르, 프리도피딘의 상업화와 공동 개발을 위해 프릴레니아와 협력 및 라이선스 계약 체결]]>https://www.newswire.co.kr/newsRead.php?no=1010284Tue, 29 Apr 2025 09:50:00 +0900<![CDATA[Experts Set International and Multidisciplinary Collaboration As Priorities in Pulmonary Hypertension Management]]>https://www.newswire.co.kr/newsRead.php?no=1008610Wed, 02 Apr 2025 09:15:00 +0900<![CDATA[페레르, 제7차 폐고혈압 임상치료에 관한 국제 회의 개최… 폐고혈압 관리에 있어 국제 및 다학제적 협력 강조]]>https://www.newswire.co.kr/newsRead.php?no=1008613Wed, 02 Apr 2025 09:15:00 +0900<![CDATA[Ferrer is the Highest-performing Pharmaceutical Company in the World for Social and Environmental Impact According to B Corp]]>https://www.newswire.co.kr/newsRead.php?no=1006201Fri, 21 Feb 2025 10:40:00 +0900<![CDATA[비콥에 따르면 페레는 사회적 및 환경적 영향 측면에서 세계에서 가장 높은 성과를 낸 제약 회사]]>https://www.newswire.co.kr/newsRead.php?no=1006202Fri, 21 Feb 2025 10:40:00 +0900<![CDATA[Ferrer is Recognized for Its Best-in-class Ethics and Compliance Program]]>https://www.newswire.co.kr/newsRead.php?no=1005090Fri, 31 Jan 2025 14:25:00 +0900<![CDATA[페레의 윤리·컴플라이언스 프로그램, 동급 최고 수준으로 인정]]>https://www.newswire.co.kr/newsRead.php?no=1005092Fri, 31 Jan 2025 14:25:00 +0900<![CDATA[Ferrer Obtains the Distribution Rights for Treprostinil Inhalation Solution Including the Potential Indications for Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF)]]>https://www.newswire.co.kr/newsRead.php?no=990579Wed, 29 May 2024 11:55:00 +0900<![CDATA[페레, 특발성 폐섬유증 및 진행성 폐섬유증에 대한 잠재적 적응증을 포함한 트레프로스티닐 흡입액에 대한 유통권 획득]]>https://www.newswire.co.kr/newsRead.php?no=990580Wed, 29 May 2024 11:55:00 +0900<![CDATA[The World Health Organization Includes the Cardiovascular Polypill Developed by the Spanish National Centre for Cardiovascular Research and Ferrer in its List of Essential Medicines]]>https://www.newswire.co.kr/newsRead.php?no=971810Thu, 03 Aug 2023 16:15:00 +0900<![CDATA[세계보건기구, 스페인 국립 심혈관 연구 센터와 페레르가 개발한 심혈관 폴리필을 필수 의약품 목록에 포함]]>https://www.newswire.co.kr/newsRead.php?no=971812Thu, 03 Aug 2023 16:15:00 +0900<![CDATA[Ferrer Allocates, on Average, More Than 40% of its Profits to Social and Environmental Projects for the Third Consecutive Year]]>https://www.newswire.co.kr/newsRead.php?no=971493Sun, 30 Jul 2023 14:30:00 +0900<![CDATA[페레, 3년 연속 수익의 평균 40% 이상 사회 및 환경 프로젝트에 환원]]>https://www.newswire.co.kr/newsRead.php?no=971494Sun, 30 Jul 2023 14:30:00 +0900<![CDATA[Experts Call for Protocols to Speed up Referrals for Pulmonary Hypertension to Specialized Centers]]>https://www.newswire.co.kr/newsRead.php?no=969948Tue, 04 Jul 2023 10:10:00 +0900<![CDATA[전문의들, IMPAHCT서 폐고혈압 환자의 전문 센터 의뢰 속도 높이기 위한 프로토콜 요구]]>https://www.newswire.co.kr/newsRead.php?no=969953Tue, 04 Jul 2023 10:10:00 +0900<![CDATA[Ferrer Initiates its ADOREXT Extension Study in Amyotrophic Lateral Sclerosis (ALS)]]>https://www.newswire.co.kr/newsRead.php?no=969233Thu, 22 Jun 2023 10:55:00 +0900<![CDATA[페레, 근위축성측색경화증에 대한 ADOREXT 확장 연구 시작]]>https://www.newswire.co.kr/newsRead.php?no=969236Thu, 22 Jun 2023 10:55:00 +0900<![CDATA[Ferrer Acquires Worldwide Rights to ASN90, an O-GlcNAcase Inhibitor From Asceneuron, Exclusively to Treat Progressive Supranuclear Palsy (PSP)]]>https://www.newswire.co.kr/newsRead.php?no=962022Thu, 23 Feb 2023 10:35:00 +0900<![CDATA[페레, 아세뉴런의 O-GlcNAcase 억제제 ASN90 사용한 진행성 핵상마비 치료에 대한 전 세계적 독점 권리 획득]]>https://www.newswire.co.kr/newsRead.php?no=962023Thu, 23 Feb 2023 10:35:00 +0900<![CDATA[The Polypill Reduces Cardiovascular Mortality by 33% in Patients Treated After Myocardial Infarction]]>https://www.newswire.co.kr/newsRead.php?no=950234Mon, 29 Aug 2022 13:30:00 +0900